Researchers at the University of East Anglia have discovered for the first time a pathway that makes cancerous leukaemia cells resistant to treatment.
The scientists found that death-resistant Acute Myeloid Leukaemia cells are given their resistance by a genetic anti-oxidant pathway called hemeoxygenase-1 or HO-1. This resistance pathway leads to relapse of the disease and non-responsiveness to treatments. When this pathway is inhibited, the cells lose their resistance and become responsive to death-inducing agents.
Published online in the journal Blood on Friday January 18, the discovery is the first stage in the development of new drugs that could significantly improve survival rates for leukaemia sufferers.
“This is a major step forward in the treatment of leukaemia and other cancers,” said Prof David MacEwan who led the research team.
“The next step will be a programme to develop a new set of targeted therapies to treat not only Acute Myeloid Leukaemia, but other leukaemias and other cancers.”
Leukaemia is one of the six biggest cancer killers in the UK and more people die of Acute Myeloid Leukaemia (AML) than any other form of leukaemia. AML attacks the white blood cells and is a common form in both children and adults with leukaemia. It is currently treated by a range of chemotherapy drugs. Many patients go on to have bone marrow transplants due to commonly developing drug-resistance to their initial chemotherapy.
The antioxidant response element (ARE) genes which include HO-1, protect cells from damage and their killing off by cytotoxic agents such as chemotherapy drugs. The team found that drug-resistant leukaemia cells have overactive ARE genes that cause them to be completely resistant to cytotoxic drugs, and that blocking this pathway reverts the cells into responding normally to cytotoxic agents.
Source: University of East Anglia
Related stories:
Marine organisms could hold the secret to reducing cancer
Research into why a tea derived from an ancient crop from the western Pacific could be responsible for reducing the risk of cancer, is being conducted by Aberdeen experts.
Increased cancer risk following the use of radioactive Radium-224 in the therapy
Ankylosing Spondylitis (Bechterew's Disease) is a painful chronic inflammatory rheumatic disease, associated with stiffening of the vertrebral column. Between 100,000 and 150,000 cases have already been diagnosed in Germany, but milder forms of the disease may remain undiagnosed.
Connecting cancer genes
A large genetic study in mice has identified hundreds of genes involved in the development of cancer by examining the DNA of more than 500 lymphomas to find the cancer causing mutations.
Cancer could return unless stored ovarian tissue undergoes adequate testing before re-implantation
Cancer patients who have been successfully treated for their disease face the prospect of its return if stored ovarian (or testicular) tissue is transplanted back into their bodies without adequate checks, according to researchers at two university hospitals in Israel.
An unexpected way to cause leukemia
Leukaemia – cancer of blood or bone marrow – is caused by mutations that allow defective blood cells to accumulate and displace healthy blood. To devise effective therapies it is crucial to know which mutations cause leukaemia and which cell type gives rise to leukaemic cells.
Are dual cord blood banks the answer to increasing stem cell demand?
Demand for stem cells from cord blood is greater than supply. In this week’s BMJ, two senior doctors, Professors Nicholas Fisk and Rifat Atun, analyse the UK’s growing cord blood banking industry and the potential impact of a new bank that provides blood for both personal and public use.
A Taxing Issue: How Human T-lymphotropic Virus Can Cause Leukemia In Adults
Researchers have identified a potential new mechanism through which human T-lymphotropic virus type-1 (HTLV-1) causes leukemia in adults. The findings, published this week in the online open access journal
Retrovirology, represent the first time that a reduction in histone protein levels has been linked to viral infection and the development of cancer.
T vs. B: Re-engineered human T cells effectively target and kill cancerous B cells
Human white blood cells, engineered to recognize other malignant immune cells, could provide a novel therapy for patients with highly lethal B cell cancers such as acute lymphoblastic leukemia (ALL), according to researchers at Memorial Sloan-Kettering Cancer Center (MSKCC). By administering repeated doses of T cells designed to express an artificial receptor which recognizes human B cells, the researchers were able to eradicate cancer in 44 percent of mice bearing human ALL tumors.